Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

BioCis Pharma Starts A Phase I Clinical Trial With A New Cancer Drug
BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, has started Phase I clinical testing of ProtoCure(TM) intravesical instillation solution, a novel anti-cancer drug for urinary bladder cancer. ProtoCure is based on a new mechanism of action discovered and developed by BioCis Pharma which effectively prevents cancer growth and proliferation locally.
generic viagra online
Social Security Administration Considers Adding Alzheimer's To Its Compassionate Allowances List
Today there are an estimated 5.3 million Americans with Alzheimer"s disease. Although the majority of Alzheimer cases are individuals age 65 and older, there is still a significant number of individuals under age 65 impacted by this fatal disease that today has no cure. For people under age 65 with Alzheimer"s disease or a related dementia, their cognitive impairment can quickly reach a point where they can no longer maintain gainful employment. The Alzheimer"s Association applauds the Social Security Administration (SSA) for holding a hearing today to examine whether these individuals with younger-onset Alzheimer"s disease or related dementias should be included in its Compassionate Allowances Initiative.
News of the day
Law Firm Appointed To Boost Fight Against NHS Fraud
A new partnership between NHS Counter Fraud and law firm Capsticks will strengthen support to health bodies seeking to recover NHS funds lost to fraud.
Health Insurance

Society Supports GHP Protest For Pharmacist Recruitment Premium, UK

The Royal Pharmaceutical Society is backing the Guild of Healthcare Pharmacists (GHP) bid to get the Government to review its decision on the recruitment and retention premium of pharmacists in hospitals and PCTs. The Pay Review Body last week recommended that band 6 and 7 pharmacists in these areas should receive the recruitment and retention premium (RRP) from October this year, but the Government has rejected this recommendation. Steve Churton, Society President said; "The Society has concerns that the current staff shortages will adversely affect patient care and that a failure to address the problem now will only make the problem worse. We wholly support the campaign being undertaken by GHP and Unite to get the Government to rethink its decision. "We are aware of the work the Guild has done to find a workable solution to the recruitment and retention of hospital and PCT pharmacists. Its findings that there is a national problem are consistent with the Pay Review Body and its recommendation of an RRP in the short term. We intend to raise this issue with Pharmacy Minister, Mike O"Brien at the earliest possible opportunity. "We are now encouraging pharmacists to write to their MP if they agree that this decision is unfair." Pharmacists from all sectors are being urged to contact their Health Secretary/Minister and local MP asking for the decision to be reviewed. There are letter templates available from the GHP website, www.ghp.org.uk that you can add your details to and send to the appropriate MP. A list of local MP"s can also be found via this website. Royal Pharmaceutical Society of Great Britain


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009